Stay updated on Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial

Sign up to get notified when there's something new on the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the overall response rate for the combination of lenvatinib and pembrolizumab in patients with metastatic gastroesophageal cancer who have progressed on first or subsequent line therapies.
    Difference
    0.1%
    Check dated 2024-06-06T14:25:52.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as age, health conditions, and prior treatments. Previously, this section had no information provided.
    Difference
    50%
    Check dated 2024-05-22T21:14:44.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:29:19.000Z thumbnail image

Stay in the know with updates to Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galidesivir Safety/PK/Antiviral Effects in Yellow Fever/COVID-19 Clinical Trial page.